Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in Relapsed/Refractory DLBCL, MCL, and FL
NCT01693614Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of buparlisib in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), sponsored by Novartis. Started Feb 2013; status: completed.
02
Drugs
buparlisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01693614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693614.